dasatinib neoethicals 100 mg tabletas recubiertas
neoethicals - tabletas recubiertas - 100 mg
dasatinib neoethicals 70 mg tabletas recubiertas
neoethicals - tabletas recubiertas - 70 mg
dasatinib teva 50 mg comprimidos recubiertos con pelicula efg, 56 comprimidos
dasatinib teva 70 mg comprimidos recubiertos con pelicula efg, 56 comprimidos
dasatinib teva 20 mg comprimidos recubiertos con pelicula efg, 56 comprimidos
dasatinib newline pharma 20 mg comprimidos recubiertos con pelicula efg, 56 comprimi
dasatinib newline pharma 140 mg comprimidos recubiertos con pelicula efg, 30 comprim
dasatinib teva 20 mg comprimidos recubiertos con pelicula efg, 60 comprimidos
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. ver secciones 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
leunib
laboratorio varifarma s.a. argentina - dasatinib 100,0 mg - comprimidos recubiertos - cada comprimido recubierto contiene: dasatinib 100,0 mg